Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7618268 | 1.00 | CHRM2 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7622506 | 0.82 | CHRM2 (0.38) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7622510 | 0.82 | CHRM2 (0.38) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7622515 | 0.82 | CHRM2 (0.38) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7618124 | 0.81 | POLB (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7618122 | 0.81 | POLB (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL2083375 | 0.75 | — | — | |
| SCHEMBL14644332 | 0.75 | — | — | |
| SCHEMBL7619079 | 0.73 | FPR2 (0.35) | CHRM5ACEPIK3CDNPSR1 | |
| SCHEMBL7510369 | 0.73 | FPR2 (0.35) | CHRM5ACEPIK3CDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46942-E1 | 4-piperidinyl compounds for use as tankyrase inhibitors | NOVARTIS AG (CH) | 2018-07-10 | — | — | US | disclosed |
| US-RE46942-E1 | 4-piperidinyl compounds for use as tankyrase inhibitors | NOVARTIS AG (CH) | 2018-07-10 | — | — | US | disclosed |
| US-RE46942-E1 | 4-piperidinyl compounds for use as tankyrase inhibitors | NOVARTIS AG (CH) | 2018-07-10 | — | — | US | disclosed |
| US-9163003-B2 | 4-piperidinyl compounds for use as tankyrase inhibitors | NOVARTIS AG (CH) | 2015-10-20 | — | — | US | disclosed |
| US-9163003-B2 | 4-piperidinyl compounds for use as tankyrase inhibitors | NOVARTIS AG (CH) | 2015-10-20 | — | — | US | disclosed |
| US-9163003-B2 | 4-piperidinyl compounds for use as tankyrase inhibitors | NOVARTIS AG (CH) | 2015-10-20 | — | — | US | disclosed |
| EP-2731940-B1 | 4 - PIPERIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2015-08-19 | — | — | EP | disclosed |
| EP-2731940-B1 | 4 - PIPERIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2015-08-19 | — | — | EP | disclosed |
| US-20150126513-A1 | 4-PIPERIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
| US-20150126513-A1 | 4-PIPERIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
| US-20150126513-A1 | 4-PIPERIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
| EP-2731940-A1 | 4 - PIPERIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | Novartis AG (CH) | 2014-05-21 | — | — | EP | disclosed |
| WO-2013008217-A1 | 4 - PIPERIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2013-01-17 | — | — | WO | disclosed |
| WO-2013008217-A1 | 4 - PIPERIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2013-01-17 | — | — | WO | disclosed |
| EP-0620225-B1 | Cephalosporin derivatives | BASILEA PHARMACEUTICA AG (CH) | 2002-11-13 | — | — | EP | disclosed |
| US-5523400-A | 3-(PYRROLIDIN-3-YLIDENE=CH-),7-((2-AMINOTHIAZOL-4-YL)HYDROX -IMINOACETYLAMINO-)-3-CEPHEM DERIVATIVES; BROAD SPECTRUM ANTIBIOTICS | HOFFMANN-LA ROCHE INC. (US) | 1996-06-04 | — | — | US | disclosed |
| EP-0620225-A1 | Cephalosporin derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1994-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126513-A1 | 4-PIPERIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | TNKS1BP1, WNT1, TNKS | CHRM2 4325/4885CHRM4 3908/4885CHRM5 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.